• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study.
 
  • Détails
Titre

Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Journal of Hypertension  
Auteur(s)
Meier, P.
Auteure/Auteur
Maillard, M.P.
Auteure/Auteur
Meier, J.R.
Auteure/Auteur
Tremblay, S.
Auteure/Auteur
Gauthier, T.
Auteure/Auteur
Burnier, M.
Auteure/Auteur
Liens vers les personnes
Maillard, Marc  
Meier, Pascal  
Burnier, Michel  
Liens vers les unités
Néphrologie  
ISSN
1473-5598
Statut éditorial
Publié
Date de publication
2011
Volume
29
Numéro
6
Première page
1228
Dernière page/numéro d’article
1235
Langue
anglais
Résumé
Objective The goal of this study was to investigate whether increasing the dose of an angiotensin II receptor blocker (ARB) provides as much benefits as combining the ARB with an angiotensin-converting enzyme inhibitor (ACEI) in terms of blood pressure (BP) control and urinary albumin excretion (UAE) in hypertensive patients with a proteinuria.Methods We enrolled 20 hypertensive patients with proteinuric nephropathies and a reduced renal function in a randomized, 12-month, triple-crossover, prospective, open-label study to compare the effects of a regular dose of losartan (Los 100mg q.d., LOS100) vs. a high dose of losartan (Los 100mg b.i.d., LOS200) vs. losartan 100mg q.d. associated with lisinopril 20 mg q.d. (LOS100 + LIS20). Each treatment was given for 8 weeks with a 4-week initial run-in period and 2 weeks of washout between each treatment phases. 24 h UAE and ambulatory BP were measured during the running phase and at the end of each treatment period.Results Compared to pretreatment, 24 h SBP and DBP were reduced by 10/5 +/- 7/4 mmHg with LOS100 (P=0.023 vs. baseline) and, respectively, 13/6 +/- 12/5 mmHg with LOS200 (P=0.011) and 19/9 +/- 15/8 mmHg with LOS100+LIS20 (P < 0.01). UAE decreased significantly with LOS100 and to an even greater degree with LOS200 and LOS100+LIS20 (P < 0.01 vs. baseline for both and P=0.032, LOS100+LIS20 vs. LOS200). The combination had a greater impact in patients with a high baseline proteinuria as suggested by a nonparallel leftward shift of the relationship between the changes in UAE induced by the combination and those induced by LOS200. The high dose of losartan was better tolerated than the combination.Conclusion Increasing the dose of losartan from 100mg once daily to 100mg twice a day enables to obtain a greater decrease in BP and proteinuria and is better tolerated than combining the ARB with lisinopril, though the high dose appears to be slightly less effective than the combination in patients with a marked proteinuria. J Hypertens 29: 1228-1235 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
PID Serval
serval:BIB_C9943169D7DF
DOI
10.1097/HJH.0b013e328346d5dc
PMID
21505349
WOS
000290251500028
Permalien
https://iris.unil.ch/handle/iris/135907
Date de création
2011-05-25T07:51:59.265Z
Date de création dans IRIS
2025-05-20T21:17:10Z
  • Copyright © 2024 UNIL
  • Informations légales